Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 3, 2006, Pages 645-650

  Garey, Kevin W ^a,b   Dao, Thanh ^b   Chen, Hua ^a   Amrutkar, Paresh ^a   Kumar, Nandan ^a   Reiter, Margaret ^b   Gentry, Layne O ^b  

^a UNIVERSITY OF HOUSTON   (United States)

^b ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

Antibacterial agents administration and dosage; Antibiotic surgical prophylaxis; Prospective study; Surgical wound infection prevention and control

Indexed keywords

VANCOMYCIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG INFUSION; FEMALE; HEART SURGERY; HEART VALVE REPLACEMENT; HUMAN; INCIDENCE; INCISION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT MONITORING; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; STATISTICAL MODEL; SURGICAL INFECTION; SURGICAL PATIENT; SURGICAL RISK; VALIDATION STUDY;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CARDIAC SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; SURGICAL WOUND INFECTION; VANCOMYCIN;

EID: 33747883002     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl279     Document Type: Article

References (22)

1. Shapiro M, Townsend TR, Rosner B et al. Use of antimicrobial drugs in general hospitals: Patterns of prophylaxis. N Engl J Med 1979; 301: 351-5.
2. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: An advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38: 1706-15.
3. Gyssens IC. Preventing postoperative infections: Current treatment recommendations. Drugs 1999; 57: 175-85.
4. Gorbach SL, Condon RE, Conte JE Jr et al. Evaluation of new anti-infective drugs for surgical prophylaxis. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1: S313-38.
5. Salminen US, Viljanen TU, Valtonen VV et al. Ceftriaxone versus vancomycin prophylaxis in cardiovascular surgery. J Antimicrob Chemother 1999; 44: 287-90.
6. Ellis MW, Lewis JS 2nd. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005; 18: 496-501.
7. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep 1997; 46: 626-628, 635.
8. Galandiuk S, Polk HC Jr, Jagelman DG et al. Re-emphasis of priorities in surgical antibiotic prophylaxis. Surg Gynecol Obstet 1989; 169: 219-22.
9. Classen DC, Evans RS, Pestotnik SL et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326: 281-6.
10. Horan TC, Gaynes RP, Martone WJ et al. CDC definitions of nosocomial surgical site infections, 1992: A modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol 1992; 13: 606-8.
11. Weiner BJ, Shortell SM, Alexander J. Promoting clinical involvement in hospital quality improvement efforts: The effects of top management, board, and physician leadership. Health Serv Res 1997; 32: 491-510.
12. Heckman J. Sample selection bias as a specification error. Econometrica 1979; 47: 153-62.
13. Stone HH, Hooper CA, Kolb LD et al. Antibiotic prophylaxis in gastric, biliary and colonic surgery. Ann Surg 1976; 184: 443-52.
14. Movahed MR, Kasravi B, Bryan CS. Prophylactic use of vancomycin in adult cardiology and cardiac surgery. J Cardiovasc Pharmacol Ther 2004; 9: 13-20.
15. Kachroo S, Dao T, Zabaneh F et al. Tolerance of vancomycin for surgical prophylaxis in patients undergoing cardiac surgery and incidence of vancomycin-resistant Enterococcus colonization. Ann Pharmacother 2006; 40: 381-5.
16. Finkelstein R, Rabino G, Mashiah T et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillin-resistant staphylococcal infections. J Thorac Cardiovasc Surg 2002; 123: 326-32.
17. Vuorisalo S, Pokela R, Syrjala H. Comparison of vancomycin and cefuroxime for infection prophylaxis in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998; 19: 234-9.
18. Martin C, Alaya M, Mallet MN et al. Penetration of vancomycin into mediastinal and cardiac tissues in humans. Antimicrob Agents Chemother 1994; 38: 396-9.
19. Krivoy N, Yanovsky B, Kophit A et al. Vancomycin sequestration during cardiopulmonary bypass surgery. J Infect 2002; 45: 90-5.
20. Burke JF. The effective period of preventive antibiotic action in experimental incision and dermal lesions. Surgery 1961; 50: 161-8.
21. Hollenbeak CS, Murphy DM, Koenig S et al. The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. Chest 2000; 118: 397-402.
22. Livingston DH, Shumate CR, Polk HC Jr et al. More is better. Antibiotic management after hemorrhagic shock. Ann Surg 1988; 208: 451-9.